Clinical Trials Browser

Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03257631 2024-04-16

A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

Phase 2 Completed

53 enrolled 18 charts

CNS

Brain Neoplasms, Ependymoma, Glioma, Medulloblastoma, Central Nervous System Neoplasms

NCT02188368 2023-11-03

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Phase 2 Terminated

45 enrolled

Plasma cell

Multiple Myeloma

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2 Terminated

45 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03104270 2022-03-31

Combination Study for High Risk Multiple Myeloma Patients

Phase 2 Terminated

13 enrolled

Plasma cell

Multiple Myeloma

NCT02045017 2021-08-27

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Phase 2 Completed

81 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT00463385 2019-11-20

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

Phase 2 Completed

88 enrolled 22 charts

MyeloidOther hematologic neoplasm

Leukemia, Megakaryoblastic, Acute, Primary Myelofibrosis

NCT00717522 2019-11-19

Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma

Phase 2 Terminated

7 enrolled 7 charts

Sarcoma

NCT02011113 2016-11-01

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 2 Completed

36 enrolled 18 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT00072722 2006-12-19

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

Phase 2 Completed

36 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

DREAMM5

SELECT

POM MM 014

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Combination Study for High Risk Multiple Myeloma Patients

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)